Target Price | $32.20 |
Price | $3.62 |
Potential |
789.50%
register free of charge
|
Number of Estimates | 5 |
5 Analysts have issued a price target Cingulate 2026 .
The average Cingulate target price is $32.20.
This is
789.50%
register free of charge
$62.00
1,612.71%
register free of charge
$8.00
120.99%
register free of charge
|
|
A rating was issued by 4 analysts: 4 Analysts recommend Cingulate to buy, 0 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Cingulate stock has an average upside potential 2026 of
789.50%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -10.20 | -3.31 |
96.73% | 67.55% | |
P/E | negative |
1 Analysts have issued a Cingulate forecast for earnings per share. The average Cingulate EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
Roth Capital |
Locked
➜
Locked
|
Locked | May 19 2025 |
Ascendiant Capital |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 30 2025 |
Roth MKM |
Locked
➜
Locked
|
Locked | Jan 10 2025 |
Maxim Group |
Locked
➜
Locked
|
Locked | Nov 20 2024 |
Analyst Rating | Date |
---|---|
Locked
Roth Capital:
Locked
➜
Locked
|
May 19 2025 |
Locked
Ascendiant Capital:
Locked
➜
Locked
|
Apr 21 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 06 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 30 2025 |
Locked
Roth MKM:
Locked
➜
Locked
|
Jan 10 2025 |
Locked
Maxim Group:
Locked
➜
Locked
|
Nov 20 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.